ARHGAP12

Across TCGA pan-cancer cohorts, ARHGAP12 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGAP12 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARHGAP12 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGAP12 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

UCEC, LUAD, and HNSC are the cancer types where ARHGAP12 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.978	0.598	<.001	32	view →
LUAD	OS	Median	All	0.275	0.790	.004	9	view →
HNSC	OS	Median	All	0.187	0.603	.028	3	view →
SKCM	DFS	Median	III,IV	0.046	0.648	<.001	3	view →
LUSC	DFS	Median	All	1.000	0.385	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGAP12–UCEC (DFS)

Open the UCEC breakdown →